

**REMARKS**

The active claims in this case are claims 5, 7-10, and 13-27.

Applicants have elected in the present the subject matter of the group II invention as identified in the Restriction Requirement dated 9/08/95 in parent application serial number 08/251,574.


A petition to revive the '574 parent application and to file a separate RCE has been filed concurrently herewith.

With respect to the new claims and amendments, 1) support for the various biological response modifiers can be found at the bottom of page 10, 2) support for the various antibodies can be found on pages 11-12, and 3) support for the concept of diagnosing patients as having tumors with a specific antigenic determinant can be found at the top of page 15.

It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason, the Commissioner is authorized to deduct said fees from Fulbright &

Jaworski L.L.P. Account No.: 50-1212/CLFR:029USD1

Respectfully submitted,

  
David L. Parker  
Reg. No. 32,165  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201  
(512) 536-4598 (facsimile)

Date: October 1, 2003